Review – Kidney CancerSystematic Review of Oncological Outcomes Following Surgical Management of Localised Renal Cancer
Introduction
Renal cell carcinoma (RCC) accounts for approximately 2–3% of all adult malignancies. More than 50% of all RCCs diagnosed are a localised stage (ie, T1–T2N0M0 or stage I–II) [1]. Open radical nephrectomy has been the standard curative intervention for localised RCC for the past five decades [2]. There were controversies over whether radical nephrectomy should be performed in conjunction with ipsilateral adrenalectomy, as originally described by Robson, or if the adrenal should be preserved [3], [4], [5], [6] and whether ipsilateral extended retroperitoneal lymphadenectomy or limited hilar lymphadenectomy should be performed [7], [8].
With the advent of minimally invasive surgery, laparoscopic radical nephrectomy has become an acceptable alternative to open surgery for localised RCCs [6], [7]. Another recent controversy is the use of nephron-sparing surgery (NSS; partial nephrectomy). NSS has been the accepted mode of treatment when radical nephrectomy would render the patient anephric or at high risk for subsequent renal replacement therapy [9]. This organ-preserving approach has recently emerged as a viable alternative for small renal tumours (<4 cm or T1a) in patients with a normal contralateral kidney, with encouraging short-term and long-term oncological outcomes [10], [11]. The era of increasing use of NSSs has also witnessed the development of minimally invasive nephron-sparing interventions such as cryoablation, radiofrequency ablation (RFA), and high-intensity focussed ultrasound (HIFU) for the treatment of localised renal cancer [10], [11].
Although various guidelines exist in relation to the various interventions for localised RCC [6], [12], it is important to recognise that such guidelines were based on reviews that were not undertaken systematically and often used methodology that was not transparent, reproducible, or robust. A systematic review of current evidence is urgently needed to establish whether the outcomes of competing treatment options are comparable. Methodological rigour is needed in assessing risks of bias and quality of evidence in a standardised and transparent way to highlight weaknesses in the evidence base and to make recommendations for future research.
The objective of this systematic review was to compare the oncological outcomes for all interventions relevant to the management of localised RCC. This paper reports the oncological outcomes, and a separate article reports the surgical and quality-of-life outcomes from this systematic review. There is also a full report published online with extra methodological information and data for oncological and surgical outcomes [13].
Section snippets
Search strategy
The databases searched were Medline (1950 to October 2010) and Embase (1980 to October 2010), Cochrane Library, all sections (Issue 4, 2010), Web of Science, with Conference Proceedings (1970 to October 2010), and American Society of Clinical Oncology meeting abstracts (up to October 2010). The searches were not limited by language. Auto-alerts in Medline were also run during the course of the review. Reference lists of relevant articles were also checked [13]. Two reviewers screened all
Risk of bias and quality assessment of the included studies
The study selection process is outlined in the Preferred Reporting Items for Systematic Reviews (PRISMA) diagram (Fig. 1). There were 44 studies that met inclusion criteria, and 34 of them reported oncological outcomes (6 RCTs and 28 NRSs). The Cochrane risk of bias assessment can be viewed in Appendix 1. The additional NRS risk of bias assessment adjustment scores (outlined earlier) are displayed in Table 1, which reports baseline characteristics (all study designs) and adjustment scores (NRSs
Conclusions
Patient and tumour characteristics permitting, the current oncological outcomes evidence base suggests that localised RCCs are best managed by NSS rather than by radical nephrectomy irrespective of surgical approach. Where open surgery is deemed necessary, open NSS oncological outcomes are at least as good as open radical nephrectomy and should be the preferred option when technically feasible. The evidence around minimally invasive ablative technologies is weak due to low methodological
References (62)
- et al.
The results of radical nephrectomy for renal cell carcinoma
J Urol
(1969) - et al.
Reconsidering the necessity of ipsilateral adrenalectomy during radical nephrectomy for renal cell carcinoma
Urology
(1995) - et al.
Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm
J Urol
(2001) - et al.
Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy
J Urol
(2004) - et al.
EAU guidelines on renal cell carcinoma: the 2010 update
Eur Urol
(2010) - et al.
Nephron-sparing surgery as the new gold standard for T1 <= 7 cm renal cell carcinoma: results of a contemporary UCLA series
J Urol
(2004) - et al.
Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881
Eur Urol
(2009) - et al.
Nephron sparing surgery for renal tumors: indications, techniques and outcomes
J Urol
(2001) - et al.
Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies
Eur Urol
(2011) - et al.
Treatment of localised renal cell carcinoma
Eur Urol
(2011)
Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison
J Urol
Prospective randomized comparison of transperitoneal versus retroperitoneal laparoscopic radical nephrectomy
J Urol
Prospective, randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy
Urology
Approach and specimen handling do not influence oncological perioperative and long-term outcomes after laparoscopic radical nephrectomy
J Urol
What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma
J Urol
Management of small unilateral renal cell carcinomas: radical versus nephron-sparing surgery
Urology
Perioperative efficacy of laparoscopic partial nephrectomy for tumors larger than 4 cm
Eur Urol
Radical nephrectomy is not superior to nephron sparing surgery in PT1B-PT2N0M0 renal tumours: a matched comparison analysis in 546 cases
Eur Urol Suppl
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience
J Urol
Contemporary use of partial nephrectomy at a tertiary care center in the United States
J Urol
Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses
J Urol
Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment
Urology
Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors
J Urol
7-year oncological outcomes after laparoscopic and open partial nephrectomy
J Urol
Laparoscopic and open partial nephrectomy: a matched-pair comparison of 200 patients
Eur Urol
Laparoscopic partial nephrectomy versus laparoscopic cryoablation for the small renal tumor
Urology
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma
Eur Urol
Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates
J Vasc Interv Radiol
Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999–2001
Cancer Epidemiol Biomarkers Prev
Cited by (285)
Radical versus partial nephrectomy for T1 non-clear cell renal cell carcinoma
2023, European Journal of Surgical OncologyEuropean Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update
2022, European UrologyImproving Guideline Adherence in Urology
2022, European Urology Focus